ETON
Eton Pharmaceuticals, Inc.NASDAQHealthcare$24.99+0.04%ClosedMarket Cap: $681.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
25.72
P/S
8.53
EV/EBITDA
173.88
DCF Value
$-38.21
FCF Yield
-0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.5%
Operating Margin
-1.1%
Net Margin
-5.8%
ROE
-18.8%
ROA
-5.0%
ROIC
-1.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $21.3M | 61.6% | $2.5M | $1.5M | $0.05 | — |
| FY 2025 | $80.0M | 53.5% | $72.0K | $-4.6M | $-0.17 | — |
| Q3 2025 | $22.5M | 35.0% | $-1.4M | $-1.9M | $-0.07 | — |
| Q2 2025 | $18.9M | 63.0% | $-1.5M | $-2.6M | $-0.10 | — |
| Q1 2025 | $17.3M | 57.1% | $-470.0K | $-1.6M | $-0.06 | — |
| Q4 2024 | $11.6M | 55.6% | $629.0K | $-598.0K | $-0.02 | — |
| FY 2024 | $39.0M | 60.0% | $-2.6M | $-3.8M | $-0.15 | — |
| Q3 2024 | $10.3M | 61.0% | $509.0K | $627.0K | $0.02 | — |
| Q2 2024 | $9.1M | 62.0% | $-2.9M | $-3.0M | $-0.12 | — |
| Q1 2024 | $8.0M | 62.9% | $-800.0K | $-811.0K | $-0.03 | — |
| Q4 2023 | $7.3M | 49.6% | $-2.0M | $-2.3M | $-0.09 | — |
| FY 2023 | $31.6M | 66.6% | $-1.2M | $-936.0K | $-0.04 | — |